Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) dropped 6.1% during trading on Monday after an insider sold shares in the company. The company traded as low as $10.50 and last traded at $10.51. Approximately 3,359,534 shares traded hands during trading, a decline of 54% from the average daily volume of 7,262,308 shares. […]
Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its target price upped by Needham & Company LLC from $15.00 to $17.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also recently issued reports on RXRX. TD Cowen initiated coverage on Recursion Pharmaceuticals […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) COO Tina Marriott sold 8,000 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $14.89, for a total value of $119,120.00. Following the completion of the sale, the chief operating officer now owns 639,982 shares […]
Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading Volume themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Baillie Gifford & Co. lowered its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 2.2% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 24,551,409 shares of the company’s stock after selling 546,221 shares during the period. Baillie Gifford & Co. owned approximately 11.39% […]